Metatissue took part in the first general assembly meeting of the MITI² project in Zaragoza.
On May 21 and 22, Metatissue was represented by Ana Rufino and Inês Deus at the first general assembly meeting of the MITI² project consortium, which took place in Zaragoza, Spain.
Metatissue had the honor of participating in the first meeting of the MITI² project’s General Assembly, which took place in Zaragoza, Spain, on May 21 and 22. The event was attended by all the consortium’s partners, who met to present the scientific progress made so far and discuss the project’s next steps.
The General Assembly was accompanied by a workshop on organ-on-chip technologies, held at Beonchip’s facilities. This workshop provided a valuable opportunity for the consortium members to exchange knowledge and experiences.

The MITI² project, funded by the European Commission and coordinated by Frédéric Altare (Inserm), brings together seven partners from four countries and is at the forefront of research into a new cell-based immunotherapy approach for patients with Inflammatory Bowel Disease. The initiative uses an innovative ex vivo human preclinical model, based on organ-on-chip technology, combined with a cutting-edge bioprinting method.
This meeting represents an important milestone in the collaborative efforts to promote new therapeutic options for IBD patients. The productive discussions and innovative exchanges held during the event will certainly boost the progress of the MITI² project.
For more information on the MITI² consortium, visit www.miti2.eu.